DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Mariam Sunny - 3 Bhanvi - 2 Lucy Nicholson - 1 Stephens - 1 Scott Fidel - 1 UnitedHealth - 1 Shounak Dasgupta - 1 Eli Lilly - 1
Top related locs:
Bengaluru U.S COVID Branchburg , New Jersey White Oak , Maryland
Top related orgs:
REUTERS - 3 Thomson - 3 Humana - 1 Company - 1 Novo Nordisk - 1 Food and Drug Administration - 1 FDA - 1 Sage Therapeutics - 1

Search resuls for: "Bhanvi Satija Mariam E Sunny"


4 mentions found


☆ UnitedHealth profit beats on lower-than-feared medical costs
  + stars: | 2023-10-13 | by ( Bhanvi Satija Mariam E Sunny | Bhanvi Satija | Mariam E Sunny | ) www.reuters.com   time to read: +2 min
[1/2] A UnitedHealth Group health insurance card is seen in a wallet in this picture illustration October 14, 2019. REUTERS/Lucy Nicholson/Illustration/File Photo Acquire Licensing RightsOct 13 (Reuters) - UnitedHealth (UNH.N) reported a third-quarter profit on Friday ahead of analysts' estimates, helped by a lower-than-feared rise in medical costs at the company's health insurance unit. UnitedHealth's profit beat and slight raise in annual forecast set the stage for other insurers in the industry that suffered a nearly $60-billion wipeout in market value in June, on fears of a spike in medical costs. UnitedHealth said in July it expects quarterly medical costs to be "a little bit lower" sequentially. In the third quarter, the company's medical loss ratio, the percentage of spend on claims compared to premiums collected, was 82.3%, versus 83.2% in the second quarter.
Persons: Lucy Nicholson, Stephens, Scott Fidel, UnitedHealth, Mariam Sunny, Bhanvi, Shounak Dasgupta Organizations: REUTERS, Humana, Thomson Locations: COVID, Bengaluru
☆ Eli Lilly raises forecasts as diabetes drug Mounjaro powers upbeat results
  + stars: | 2023-08-08 | by ( Bhanvi Satija Mariam E Sunny | Bhanvi Satija | Mariam E Sunny | ) www.reuters.com   time to read: +2 min
An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File PhotoAug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts after beating estimates for quarterly results, driven by strong demand for its new diabetes drug Mounjaro, ahead of a decision on its use as a weight-loss treatment. The company is leaning on Mounjaro, approved last May in the U.S. for diabetes, to soften the hit from insulin price cuts and competition for cancer therapy Alimta. A decision on Mounjaro to treat obesity, expected later this year, could help the drugmaker tap a multi-billion dollar market. Lilly now expects annual revenue in range of $33.4 billion to $33.9 billion, compared with its prior range of $31.2 billion to $31.7 billion.
Persons: Eli Lilly, Mike Segar, Mounjaro, Wells, Mohit Bansal, Lilly, Bhanvi Satija, Mariam Sunny, Sriraj Organizations: Company, REUTERS, Novo Nordisk, Thomson Locations: Branchburg , New Jersey, U.S, Bengaluru
☆ Biogen, Sage face uphill battle with postpartum depression pill
  + stars: | 2023-08-07 | by ( Bhanvi Satija Mariam E Sunny | Bhanvi Satija | Mariam E Sunny | ) www.reuters.com   time to read: +2 min
REUTERS/Andrew Kelly/File PhotoAug 7 (Reuters) - The U.S. drug regulator's approval of Biogen (BIIB.O) and Sage Therapeutics' (SAGE.O) first-of-its-kind postpartum depression (PPD) pill is unlikely to allay the drugmakers' growth concerns, analysts said on Monday. Adverse commentary after their PPD drug was approved by the U.S. Food and Drug Administration (FDA) on Friday sent Sage shares tumbling 40%, while Biogen dropped 3% in premarket trading. Zurzuvae's use as a clinical depression treatment represents a more than $1 billion sales opportunity compared with $250 million to $500 million potential for postpartum depression, said Jefferies analyst Michael Yee. "Postpartum depression is not necessarily where a big commercial opportunity is," Biogen CEO Christopher Viehbacher said last month. The U.S. FDA said last week that additional studies might be required to support the drug's approval for major depressive disorder (MDD), or clinical depression.
Persons: Andrew Kelly, Sage, Biogen, Baird, Brian Skorney, Skorney, Zurzuvae, Jefferies, Michael Yee, Christopher Viehbacher, Yee, Mariam Sunny, Bhanvi, Manas Mishra, Vinay Dwivedi Organizations: Food and Drug Administration, FDA, REUTERS, Sage Therapeutics, U.S . Food, Drug Administration, U.S, Thomson Locations: White Oak , Maryland, U.S, Bengaluru
☆ WHO says infertility affects 1 in 6 globally, calls for more consistent data
  + stars: | 2023-04-03 | by ( Bhanvi Satija Mariam E Sunny | Bhanvi Satija | Mariam E Sunny | ) www.reuters.com   time to read: +2 min
April 3 (Reuters) - About one in six adults globally have experienced infertility at least once in their life, the World Health Organization (WHO) said in a report on Monday, urging countries to actively collect more consistent data on the disease. "Based on the data we have, we cannot say that infertility is increasing or constant ... the jury's still out on that question," he said, citing that data so far has been mixed and inconsistent. The report highlights the need for countries to collect and share consistent data on infertility, separated by age and cause, as well as information on those who need fertility care. About 17.8% of adults in high-income countries have experienced infertility at least once and about 16.5% of adults in low- and middle-income countries, according to the report. Reporting by Bhanvi Satija and Mariam Sunny in Bengaluru; Editing by Devika SyamnathOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 4